Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and a leading cause of death worldwide. The hyperactivated cell survival signaling pathways cause resistance to conventional chemotherapeutics so that targeted therapies could extend patient survival for only a few months. Furthermore, there are limited chemotherapeutics for HCC patients due to impaired liver functions. Thus, it is vital to determine repurposed drugs and drug combinations in HCC treatment